This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Data From A New Study On Diagnocure's GCC Assay Show Positive Results For Predicting Risk Of Colon Cancer Recurrence

Stocks in this article: CUR

Previstage TM  GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting

QUEBEC CITY, June 3, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) today reported that results of a new study were presented on Sunday, June 2, during the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. The abstract of the presentation entitled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts)" (Abstract #3639), by Dr. Daniel J. Sargent, Professor of Biostatistics and Oncology at Mayo Clinic, and colleagues, is now available on the American Society of Clinical Oncology's website,

"We believe this new study provides very strong evidence that measuring the expression level of GCC in lymph nodes is central to improved staging for patients diagnosed with node-negative colon cancer." said Dr Yves Fradet, President and Chief Medical Officer of DiagnoCure. "Prognostic risk stratification in stage II colon cancer remains a very clinically important issue and the ability of our Previstage TM GCC test to predict recurrence independently of traditional histopathology risk factors should have significant clinical impact for physicians treating colon cancer and their patients."

The VITAR retrospective study (Validating Indicators To Associate Recurrence) had been designed to assess the relationship between GCC gene expression in formalin fixed (FFPE) LNs and time to recurrence (TTR) in stage II Colon Cancer patients not treated with adjuvant chemotherapy. The second phase (called VITAR II), the results of which were presented at the 2013 ASCO meeting, focused on the positive lymph node ratio (LNR), defined as the number of nodes in which cancer cells were identified with the GCC assay, divided by the total number of nodes examined to provide recurrence risk stratification. On a validation set including 463 untreated stage II (T3N0) colon cancer patients from North American and European sites, the study showed that molecular staging based on GCC LNR status was able to predict higher recurrence risk for 195 patients (42%) treated by surgery alone. All patients had not been treated with adjuvant chemotherapy mainly because their lymph nodes appeared cancer-free by examination under the microscope, yet 10% of them had a disease recurrence or died from cancer afterwards.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs